Bio-Techne CorporationTECH
NASDAQ • Healthcare
$55.54
P/E
109.37
PEG
—
FCF Yield
—
Rev Growth YoY
+164.0% YoY
Gross Margin
6660.0%
Health Score
5/10
D/E Ratio
0.18
Confidence
LOW
Business Snapshot
Bio-Techne Corporation (ticker: TECH) is a life sciences company operating in the biotechnology sector on NASDAQ, providing reagents, instruments, and analytical tools used in biological research and clinical diagnostics. The company serves academic, pharmaceutical, and clinical laboratory customers globally. With market capitalisation data unavailable in this payload, precise cap-tier classification cannot be confirmed, though the combination of its $55.54 current price and sector profile is consistent with a mid-cap positioning.
Financial Health
**Score: 5/10** Bio-Techne's balance sheet shows genuine conservatism, with a debt-to-equity ratio of just 0.18x — well below typical biotech leverage levels — and a healthy current ratio of 3.46x, indicating solid short-term liquidity. However, several margin figures in this dataset appear anomalous: a reported gross margin of 6,660% and net margin of 658% are arithmetically implausible and likely reflect a data normalisation error, meaning true margin health cannot be reliably assessed here...
Risk Assessment
- **VALUATION: P/E of 109.37x is more than 4x the sector average of ~25x, with no PEG ratio or DCF estimate available to justify the premium.** - **DATA INTEGRITY: Reported gross margin of 6,660% and net margin of 658% are arithmetically implausible, suggesting a data error that undermines confidence in all reported financial metrics.** - **EARNINGS DETERIORATION: Earnings growth of -4,840% YoY signals a severe collapse in profitability, directly contradicting the strong revenue growth figure.** - **TECHNICALS: A confirmed death cross pattern (50-day MA crossing below 200-day MA) is a classically bearish signal; price is currently below both moving averages.** - **CASH FLOW: Free cash flow is unavailable, and the Python DCF returned N/A due to negative FCF — a meaningful concern for a stock priced at a large earnings multiple.** ---...